Results 81 to 90 of about 4,942 (259)

Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3

JIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Persistent chylomicronemia is associated with severe hypertriglyceridemia (sHTG) and plasma triglycerides (TG) levels sustainably > 10 mmol/L (880 mg/dL) despite lipid lowering therapies. The main risk of persistent chylomicronemia is acute pancreatitis (AP). During the second and third trimester of pregnancy, TG levels significantly increase,
Miriam Larouche, Diane Brisson, Nathalie Roy, Claudy Grenon, Paul Poirier, Ma'an Muhsin, Daniel Gaudet   +6 more
wiley   +1 more source

Pooled Safety and Efficacy of Inclisiran in Patients With Statin Intolerance (ORION-10 and ORION-11) [PDF]

, 2023
B. McQuillan, R. Scott Wright, David Kallend, Frederick J. Raal, Robert M. Stoekenbroek, Wolfgang Köenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, P. Wijngaard, John J.P. Kastelein, Kausik K. Ray   +11 more
openalex   +1 more source

PCSK9 Biology and Its Role in Atherothrombosis [PDF]

, 2021
It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 (PCSK9), was described.
Barale, Cristina, Melchionda, Elena, Morotti, Alessandro, Russo, Isabella   +3 more
core   +1 more source

Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field

Current Atherosclerosis Reports
A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.
Francesco Di Giacomo-Barbagallo, N. Andreychuk, Roberto Scicali, Ana González-Lleó, S. Piro, Lluís Masana, D. Ibarretxe   +6 more
semanticscholar   +1 more source

The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Aim This network meta‐analysis (NMA) evaluated four novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for hypercholesterolemia management, comparing their lipid‐lowering efficacy and safety. Methods We systematically identified randomized controlled trials employing the frequentist NMA method to assess reductions in low ...
Sihua Wang, Chenyu Li, Duncong Fan, Arquimedes Gasparotto Junior   +3 more
wiley   +1 more source

Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15

Journal of atherosclerosis and thrombosis
Aim: To evaluate the efficacy, safety, and pharmacokinetics (PK) of inclisiran in Japanese patients with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).
Shizuya Yamashita, A. Kiyosue, Pierre Maheux, Jorge Mena-Madrazo, Anastasia Lesogor, Qing Shao, Yuko Tamaki, Hidekazu Nakamura, Mizuki Akahori, Kouji Kajinami   +9 more
semanticscholar   +1 more source

Modeling and Simulation Identifies Endocytosis Uptake Rate and Fraction Unbound as Important Predictors of Oligonucleotide Pharmacokinetics

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 2065-2073, December 2025.
ABSTRACT Therapeutic oligonucleotides (TOs) represent an emerging modality, which offers a promising alternative treatment option, particularly for intracellular targets. The two types of TOs, antisense oligonucleotides (ASO) and small interfering RNAs (siRNAs), distribute highly into tissues, especially into the liver and the kidneys.
Felix Stader, Abdallah Derbalah, Adriana Zyla, Cong Liu, Iain Gardner, Armin Sepp   +5 more
wiley   +1 more source

Observational study of inclisiran effectiveness in Moscow healthcare

Российский кардиологический журнал, 2023
Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the ...
A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. Yu. Vasilyeva   +4 more
doaj   +1 more source

PCSK9 Loss‐of‐Function Disrupts Cellular Microfilament Network via LIN28A/HES5/JMY Axis in Neural Tube Defects

Advanced Science, Volume 12, Issue 41, November 6, 2025.
PCSK9 acts as a molecular chaperone promoting LIN28A lysosomal degradation. LIN28A elevates transcription factor HES5, increasing JMY expression. PCSK9 loss causes neural tube defects (NTDs) by disrupting the LIN28A/HES5/JMY axis, and high JMY disorganizes the neural progenitor cell microfilament network, leading to incomplete neural tube structure in ...
Xiaoshuai Li, Rui Wang, Wenting Luo, Hui Gu, Tianchu Huang, Qiushi Wang, Zhengwei Yuan   +6 more
wiley   +1 more source

Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy [PDF]

, 2020
Introduction: Cardiovascular disorders are one of the leading causes of mortality and morbidity worldwide. Recent advances showed a promising role of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a critical player in regulating plasma LDL ...
A. Alliaj, A. Zambon, A.L. Catapano, A.M. Malvandi, L. Canclini, P. Magni   +5 more
core   +1 more source